Kyowa Hakko Kirin Co., Limited

Kyowa Hakko Kogyo Co., Ltd.

Keiko Kawashima

Yutaka Kanda

Shinji Nara

Hiromi Ando

Yukimasa Shiotsu

Fumihiko Kanai

Tomoki Naoe

Hitoshi Kiyoi

Yoshihisa Ohta

Hiroshi Umehara

Motoki Miyama

Takeshi Takahashi

Yoshinori Yamashita

Takamasa Sugita

Masayo Suzuki

Hisashi Tagaya

Hiroaki Nakamura

Tomoyuki Nakazato

Shinji c/o Drug Discovery Research Laboratories Kyowa Hakko Kirin Co Ltd Nara

Fumihiko c/o Head Office Kyowa Hakko Kirin Co Ltd Kanai

Yoshihisa c/o Head Office Kyowa Hakko Kirin Co Ltd Ohta

Yukimasa c/o Biologics Research Laboratories Kyowa Hakko Kirin Co Ltd Shiotsu

Hiroshi c/o Drug Discovery Research Laboratories Kyowa Hakko Kirin Co Ltd Umehara

Motoki c/o Head Office Kyowa Hakko Kirin Co Ltd Miyama

Hiromi c/o Head Office Kyowa Hakko Kirin Co Ltd Ando

Yutaka c/o Medical Chemistry Research Laboratories Kyowa Hakko Kirin Co Ltd Kanda

The present invention provides a compound represented by Formula (I): [wherein Rrepresents CONRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or Rand Rare combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like,Rrepresents a hydrogen atom, CONRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or Rand Rare combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group), NRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroaroyl, substituted or unsubstituted ararkyl, substituted or unsubstituted lower alkylsulfonyl or substituted or unsubstituted lower arylsulfonyl) or the like].

Indazole derivatives

The present invention provides a type I insulin-like growth factor receptor (IGF-1R) inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I): {wherein Rrepresents &#x2014;NRR[wherein Rrepresents a hydrogen atom or the like, Rrepresents substituted or unsubstituted lower alkyl, &#x2014;C(&#x2550;O)R(wherein Rrepresents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like), or the like], or the like, and Rand Rmay be the same or different and each represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxy, or the like} or a pharmaceutically acceptable salt thereof, and the like.

IGF-1R inhibitor

The present invention provides a compound represented by Formula (I): [wherein Rrepresents CONRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or Rand Rare combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like,

Growing community of inventors

Numazu, Japan

Keiko Kawashima